Page 48 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

May 24, 2021 healthcare Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continu...

- Bylvay has the potential to become first approved drug to treat all forms of PFIC - - CHMP opinion is based on the PEDFIC Phase 3 studies - - PEDFIC 1 met the bile acid (P=0.003) and pruritus

Share this article Share this article WILLINGTON, England, May 10, 2021 /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO), has today announced the launch of a U.S. Expanded Access Program for Jazz Pharmaceuticals' investigational therapy JZP458 (asparaginase Erwinia chrysanthemi (recombinant)) for the treatment of adult and pediatric patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) following hypersensitivity or silent inactivation to E. coli-derived asparaginases. JZP458 is currently under FDA review for marketing authori...

Share this article SAN DIEGO, May 5, 2021 /PRNewswire/ --  Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in regenerative technologies, is pleased to announce the TAG Investment Bankers LTD of London (TAG) – is a wholly owned subsidiary aimed at delivering stem cell-based treatments for the acute phase of COVID-19, along with the chronic phase (known as Long COVID). GIOSTAR launches subsidiary to combat COVID-19 and Long COVID in collaboration with TAG Investment Bankers GIOSTAR is pleased to officially announce its pre-IPO fund raising round, the deta...

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici, have received a ...